ITabMed key facts
- Developer of immunotherapy drugs for treatment of cancer.
- It has raised $20.0M; the latest was Secondary Transaction - Private in Mar 2025.
- Notable investors include Changxing Fund, 3E Bioventures Capital, Peak Valley Capital, Yongjin Group, Binhai Venture Capital.
- Status: Privately Held (backing).
- ·Watch ITabMed: the Monday email on marks, rounds and moves
ITabMed funding rounds
No funding rounds for ITabMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
ITabMed investors
5 investors are on record for ITabMed, including Changxing Fund, 3E Bioventures Capital, Peak Valley Capital and Yongjin Group.
About ITabMed
Developer of immunotherapy drugs for treatment of cancer. The company's immunotherapy antibody technology platform has produced two products, A-319 and A-337, that have entered clinical phase I studies, and there are multiple candidate drug molecules in different preclinical development stages.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- itabmed.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
ITabMed doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.